Molecular pathology of myelodysplastic syndromes: Biology of medullary stromal and hematopoietic cells (Review)

被引:9
作者
Kitagawa, Masanobu [1 ]
Kurata, Morito [1 ]
Yamamoto, Kouhei [1 ]
Abe, Shinya [1 ]
Suzuki, Shiho [1 ]
Umeda, Shigeaki [1 ]
机构
[1] Tokyo Med & Dent Univ, Grad Sch, Dept Comprehens Pathol, Bunkyo Ku, Tokyo 1138519, Japan
关键词
myelodysplastic syndromes; stromal cell; hematopoietic cell; apoptosis; BONE-MARROW-CELLS; ACUTE MYELOID-LEUKEMIA; TOLL-LIKE RECEPTORS; PROGNOSTIC-SIGNIFICANCE; UNIPARENTAL DISOMY; CLINICAL-RELEVANCE; GROWTH-FACTOR; GENE ASXL1; MUTATIONS; ANEMIA;
D O I
10.3892/mmr.2011.493
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myelodysplastic syndromes (MDS) have been defined as a disease entity based on clinical features and morphological findings. Despite similarities in clinical manifestations, genetic abnormalities occurring in hematopoietic cells are heterogeneous among the syndromes. However, recent investigations have revealed that there are common biological events in the bone marrow of MDS cases. Most notably, excessive apoptosis of hematopoietic cells was observed to be induced by the bone marrow microenvironment. The apoptosis was mediated by paracrine as well as autocrine factors, suggesting that medullary stromal and hematopoietic cells play a role in the pathology of disease. Pro-inflammatory cytokines, such as TNF alpha, in the bone marrow microenvironment are predominantly paracrine mediators of apoptosis. Regarding autocrine stimulation mechanisms, it has recently been shown that the deregulation of ribosomal protein is capable of initiating a stress response in the hematopoietic cell through a p53-mediated signaling pathway. Thus, both the stromal cells of the bone marrow microenvironment and hematopoietic cells themselves possess a common and characteristic biology in this heterogeneous disease entity.
引用
收藏
页码:591 / 596
页数:6
相关论文
共 64 条
[1]   Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies [J].
Abdel-Wahab, Omar ;
Mullally, Ann ;
Hedvat, Cyrus ;
Garcia-Manero, Guillermo ;
Patel, Jay ;
Wadleigh, Martha ;
Malinge, Sebastien ;
Yao, JinJuan ;
Kilpivaara, Outi ;
Bhat, Rukhmi ;
Huberman, Kety ;
Thomas, Sabrena ;
Dolgalev, Igor ;
Heguy, Adriana ;
Paietta, Elisabeth ;
Le Beau, Michelle M. ;
Beran, Miloslav ;
Tallman, Martin S. ;
Ebert, Benjamin L. ;
Kantarjian, Hagop M. ;
Stone, Richard M. ;
Gilliland, D. Gary ;
Crispino, John D. ;
Levine, Ross L. .
BLOOD, 2009, 114 (01) :144-147
[2]   Many ribosomal protein genes are cancer genes in zebrafish [J].
Amsterdam, A ;
Sadler, KC ;
Lai, K ;
Farrington, S ;
Bronson, RT ;
Lees, JA ;
Hopkins, N .
PLOS BIOLOGY, 2004, 2 (05) :690-698
[3]   Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? [J].
Andreakos, E ;
Foxwell, B ;
Feldmann, M .
IMMUNOLOGICAL REVIEWS, 2004, 202 :250-265
[4]   A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome [J].
Barlow, Jillian L. ;
Drynan, Lesley F. ;
Hewett, Duncan R. ;
Holmes, Luke R. ;
Lorenzo-Abalde, Silvia ;
Lane, Alison L. ;
Jolin, Helen E. ;
Pannell, Richard ;
Middleton, Angela J. ;
Wong, See Heng ;
Warren, Alan J. ;
Wainscoat, James S. ;
Boultwood, Jacqueline ;
McKenzie, Andrew N. J. .
NATURE MEDICINE, 2010, 16 (01) :59-U93
[5]   Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes [J].
Bellamy, WT ;
Richter, L ;
Sirjani, D ;
Roxas, C ;
Glinsmann-Gibson, B ;
Frutiger, Y ;
Grogan, TM ;
List, AF .
BLOOD, 2001, 97 (05) :1427-1434
[6]   Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution [J].
Bernasconi, P ;
Klersy, C ;
Boni, M ;
Cavigliano, PM ;
Calatroni, S ;
Giardini, I ;
Rocca, B ;
Zappatore, R ;
Caresana, M ;
Quarna, J ;
Lazzarino, M ;
Bernasconi, C .
LEUKEMIA, 2005, 19 (08) :1424-1431
[7]   World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes [J].
Bernasconi, Paolo ;
Klersy, Catherine ;
Boni, Marina ;
Cavigliano, Paola M. ;
Calatroni, Silvia ;
Giardini, Ilaria ;
Rocca, Barbara ;
Zappatore, Rita ;
Caresana, Marilena ;
Dambruoso, Irene ;
Lazzarino, Mario ;
Bernasconi, Carlo .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (03) :193-205
[8]   Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia [J].
Boultwood, J. ;
Perry, J. ;
Pellagatti, A. ;
Fernandez-Mercado, M. ;
Fernandez-Santamaria, C. ;
Calasanz, M. J. ;
Larrayoz, M. J. ;
Garcia-Delgado, M. ;
Giagounidis, A. ;
Malcovati, L. ;
Della Porta, M. G. ;
Jadersten, M. ;
Killick, S. ;
Hellstrom-Lindberg, E. ;
Cazzola, M. ;
Wainscoat, J. S. .
LEUKEMIA, 2010, 24 (05) :1062-1065
[9]   EVI1 induces myelodysplastic syndrome in mice [J].
Buonamici, S ;
Li, DL ;
Chi, YQ ;
Zhao, R ;
Wang, XR ;
Brace, L ;
Ni, HY ;
Saunthararajah, Y ;
Nucifora, G .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (05) :713-719
[10]   Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].
Byrd, JC ;
Mrózek, K ;
Dodge, RK ;
Carroll, AJ ;
Edwards, CG ;
Arthur, DC ;
Pettenati, MJ ;
Patil, SR ;
Rao, KW ;
Watson, MS ;
Koduru, PRK ;
Moore, JO ;
Stone, RM ;
Mayer, RJ ;
Feldman, EJ ;
Davey, FR ;
Schiffer, CA ;
Larson, RA ;
Bloomfield, CD .
BLOOD, 2002, 100 (13) :4325-4336